secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001048477-25-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance
--------------------------------------------------------------------------------

- Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).
- VOXZOGO revenue $214M (+40% Y/Y) driven by global demand; Enzyme Therapies revenue $484M (+8% Y/Y) led by PALYNZIQ (+22% Y/Y).
- GAAP diluted EPS $0.95 (+107% Y/Y); non-GAAP diluted EPS $1.13 (+59% Y/Y). Operating margin expanded 16.4 ppt GAAP, 11.9 ppt non-GAAP.
- Reaffirmed full-year 2025 financial guidance; notes immaterial tariff exposure from enacted tariffs.
- Pipeline: VOXZOGO pivotal hypochondroplasia study fully enrolled; BMN 333 plan agreed with FDA; PALYNZIQ adolescent study met primary endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/0001048477-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000049/bmrn-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001048477-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer